Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Gene therapy progress and prospects: gene therapy of lysosomal storage disorders

Abstract

Despite disappointments with early clinical studies, there is continued interest in the development of gene therapy for the group of metabolic diseases referred to as lysosomal storage disorders (LSDs). The LSDs are monogenic and several small and large, representative animal models of the human diseases are available. Further, the successful reconstitution of only low and unregulated tissue levels of the affected lysosomal enzymes are expected to be sufficient to correct the disease at least in the case of some of the LSDs. For these reasons, they are perceived as good models for the evaluation of different gene delivery vectors and of different strategies for treating chronic genetic diseases by gene transfer. In this review, we will highlight the progress that has been made over the past 2 years in preclinical research for this group of disorders and speculate on future prospects.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Suzuki K . Lysosomal diseases. In: Graham DI, Lantos PL (eds) Greenfield's Neuropathology. Arnold: London, 2002, pp 653–735.

    Google Scholar 

  2. Wraith JE . Advances in the treatment of lysosomal storage disease. Dev Med Child Neurol 2001; 43: 639–646.

    Article  CAS  Google Scholar 

  3. Weinreb NJ et al. Effectiveness of enzyme replacement therapy in 1028 patients with Type I Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher registry. Am J Med 2002; 113: 112–119.

    Article  CAS  Google Scholar 

  4. Eng CM et al. Safety and efficacy of recombinant human α-galactosidase A replacement in Fabry disease. N Engl J Med 2001; 345: 9–16.

    Article  CAS  Google Scholar 

  5. Schiffman R et al. Enzyme replacement therapy in Fabry disease: a randomised controlled trial. JAMA 2001; 285: 2743–2749.

    Article  Google Scholar 

  6. Neufeld EF, Muenzer J . The mucopolysaccharidoses. In: Scriver CR, Beaudet, AL, Sly WS, Valle D (eds) The Metabolic and Molecular Basis of Inherited Disease. McGraw-Hill: New York, 2001, pp 3421–3452.

    Google Scholar 

  7. Novelli EM, Barranger JA . Gene therapy for lysosomal storage disorders. Expert Opin Biol Ther 2001; 1: 857–867.

    Article  CAS  Google Scholar 

  8. Miranda et al. Hematopoietic stem cell gene therapy leads to marked visceral organ improvements and a delayed onset of neurological abnormalities in the acid sphingomyelinase deficient mouse model of Niemann–Pick disease. Gene Therapy 2000; 7: 1768–1776.

    Article  CAS  Google Scholar 

  9. Matzner U, Habetha M, Gieselmann V . Retrovirally expressed human arylsulfatase A corrects the metabolic defect of arylsulfatase A-deficient mouse cells. Gene Therapy 2000; 7: 805–812.

    Article  CAS  Google Scholar 

  10. Qin G et al. Preselective gene therapy for Fabry disease. Proc Natl Acad Sci USA 2001; 98: 3428–3433.

    Article  CAS  Google Scholar 

  11. Leimig et al. Functional amelioration of murine galactosialidosis by genetically modified bone marrow hematopoietic progenitor cells. Blood 2002; 99: 3169–3178.

    Article  CAS  Google Scholar 

  12. Halene S, Kohn DB . Gene therapy using hematopoietic cells: sisyphus approaches the crest. Hum Gene Ther 2000; 11: 1259–1267.

    Article  CAS  Google Scholar 

  13. Horn PA et al. Highly efficient gene transfer into baboon marrow repopulating cells using GALV-pseudotype oncoretroviral vectors produced by human packaging cells. Blood 2002; 100: 3960–3967.

    Article  CAS  Google Scholar 

  14. Vigna E, Naldini L . Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2000; 2: 308–316.

    Article  CAS  Google Scholar 

  15. Cavazzana-Calvo M et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669–672.

    Article  CAS  Google Scholar 

  16. Marshall J et al. Demonstration of feasibility of in vivo gene therapy for Gaucher disease using a chemically induced mouse model. Mol Ther 2002; 6: 179–189.

    Article  CAS  Google Scholar 

  17. Du H et al. Lysosomal acid lipase deficiency: correction of lipid storage by adenovirus-mediated gene transfer in mice. Hum Gene Ther 2002; 13: 1361–1372.

    Article  CAS  Google Scholar 

  18. Przybylska MJ et al. Correction of the α-galactosidase A deficiency in Fabry mice using synthetic gene delivery vectors. Mol Ther 2002; 5: S343.

    Google Scholar 

  19. Niidome T, Huang L . Gene therapy progress and prospects: nonviral vectors. Gene Therapy 2002; 9: 1647–1652.

    Article  CAS  Google Scholar 

  20. Ross CJD et al. Treatment of a lysosomal storage disease, mucopolysaccharidosis VII, with microencapsulated recombinant cells. Hum Gene Ther 2000; 11: 2117–2127.

    Article  CAS  Google Scholar 

  21. Atthanaspoulos T, Fabb S, Dickson G . Gene therapy vectors based on adeno-associated virus: characteristics and applications to acquired and inherited diseases. Int J Mol Med 2000; 6: 363–375.

    Google Scholar 

  22. Zaiss AK et al. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 2002; 76: 4580–4590.

    Article  CAS  Google Scholar 

  23. Mount JD et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 2002; 99: 2670–2676.

    Article  CAS  Google Scholar 

  24. Jung SC et al. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice. Proc Natl Acad Sci USA 2001; 98: 2676–2681.

    Article  CAS  Google Scholar 

  25. Takahashi H et al. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer. Proc Natl Acad Sci USA 2002; 99: 13777–13782.

    Article  CAS  Google Scholar 

  26. Fraites TJ et al. Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol Ther 2002; 5: 571–578.

    Article  CAS  Google Scholar 

  27. Daly TM et al. Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer. Gene Therapy 2001; 8: 1291–1298.

    Article  CAS  Google Scholar 

  28. Fu H et al. Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery. Mol Ther 2002; 5: 42–49.

    Article  CAS  Google Scholar 

  29. Gao G et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 2002; 99: 11854–11859.

    Article  CAS  Google Scholar 

  30. Gao C, Sands MS, Haskins ME, Ponder KP . Delivery of a retroviral vector expressing human β-glucuronidase to the liver and spleen decreases lysosomal storage in mucopoly-saccharidosis VII mice. Mol Ther 2000; 2: 233–244.

    Article  CAS  Google Scholar 

  31. Stein CS et al. In vivo treatment of hemophilia A and mucopolysaccharidosis type VII using nonprimate lentiviral vectors. Mol Ther 2001; 3: 850–856.

    Article  CAS  Google Scholar 

  32. Xu L et al. Transduction of hepatocytes after neonatal delivery of a Moloney murine leukemia virus based retroviral vector results in long-term expression of β-glucuronidase in mucopolysaccharidosis VII dogs. Mol Ther 2002; 5: 141–153.

    Article  CAS  Google Scholar 

  33. Ponder KP et al. Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs. Proc Natl Acad Sci USA 2002; 99: 13102–13107.

    Article  CAS  Google Scholar 

  34. Wang L et al. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol Ther 2000; 1: 154–158.

    Article  CAS  Google Scholar 

  35. Ziegler R et al. Improved adeno-associated viral vectors for gene therapy of Fabry disease. Mol Ther 2002; 5: S91.

    Google Scholar 

  36. Daly TM et al. Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer. Gene Therapy 2001; 8: 1291–1298.

    Article  CAS  Google Scholar 

  37. Ding E et al. Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction. Mol Ther 2002; 5: 436–446.

    Article  CAS  Google Scholar 

  38. Martin-Touaux E et al. Muscle as a putative producer of acid glucosidase for glycogenosis type II gene therapy. Hum Mol Genet 2002; 11: 1637–1645.

    Article  CAS  Google Scholar 

  39. Raben N et al. Conditional tissue-specific expression of the acid α-glucosidase (GAA) gene in the GAA knockout mice: implications for therapy. Hum Mol Genet 2001; 10: 2039–2047.

    Article  CAS  Google Scholar 

  40. Agu RU et al. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res 2001; 2: 198–209.

    Article  CAS  Google Scholar 

  41. Zabner J et al. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol 2000; 74: 3852–3858.

    Article  CAS  Google Scholar 

  42. Kobinger GP, Weiner DJ, Yu QC, Wilson JM . Filovirus-pseudotyped lentiviral vector can efficiently and stably transduce airway epithelia in vivo. Nat Biotechnol 2001; 19: 225–230.

    Article  CAS  Google Scholar 

  43. Li C et al. Adenovirus-transduced lung as a portal for delivering α-galactosidase A into systemic circulation for Fabry disease. Mol Ther 2002; 5: 745–754.

    Article  CAS  Google Scholar 

  44. Auricchio A et al. Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. J Clin Invest 2002; 110: 499–504.

    Article  CAS  Google Scholar 

  45. Frisella WA et al. Intracranial injection of recombinant adeno-associated virus improves cognitive function in a murine model of mucopolysaccharidosis Type VII. Mol Ther 2001; 3: 351–358.

    Article  CAS  Google Scholar 

  46. Brooks AI et al. Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc Natl Acad Sci USA 2002; 99: 6216–6221.

    Article  CAS  Google Scholar 

  47. Consiglio A et al. In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nat Med 2001; 7: 310–316.

    Article  CAS  Google Scholar 

  48. Passini MA, Lee EB, Heuer GG, Wolfe JH . Distribution of a lysosomal enzyme in the adult brain by axonal transport and by cells of the rostral migratory stream. J Neurosci 2002; 22: 6437–6446.

    Article  CAS  Google Scholar 

  49. Xia H, Mao Q, Davidson BL . The HIV Tat protein transduction domain improves the biodistribution of β-glucuronidase expressed from recombinant viral vectors. Nat Biotechnol 2001; 19: 640–644.

    Article  CAS  Google Scholar 

  50. Clackson T . Regulated gene expression systems. Gene Therapy 2000; 7: 120–125.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cheng, S., Smith, A. Gene therapy progress and prospects: gene therapy of lysosomal storage disorders. Gene Ther 10, 1275–1281 (2003). https://doi.org/10.1038/sj.gt.3302092

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3302092

Keywords

This article is cited by

Search

Quick links